|
시장보고서
상품코드
2102571
in vitro 폐 모델 시장 규모, 점유율 및 성장 분석 : 유형별, 용도별, 세포 유래별, 최종사용자별, 질환별, 지역별 - 업계 예측(2026-2033년)In Vitro Lung Model Market Size, Share, and Growth Analysis, By Type, By Application, By Cell Source, By End User, By Disease Indication, By Region - Industry Forecast 2026-2033 |
||||||
세계의 체외 폐 모델 시장 규모는 2024년에 3억 4,160만 달러로 평가되며, 2025년 3억 9,154만 달러에서 2033년에는 2,461만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 14.62%로 성장할 것으로 전망되고 있습니다.
전 세계 체외 폐 모델 시장은 엄격한 규제 기준과 높아지는 윤리적 고려의 영향을 받아, 동물 실험을 대체할 수 있는 기법에 대한 수요가 증가하고 있는 것이 주요 성장 동력이 되고 있습니다. 기본적인 상피 배양에서 복잡한 미세유체 시스템에 이르기까지 첨단 체외 폐 플랫폼을 통해 과학자들은 인간의 생리 기능을 반영한 독성, 유효성 및 질병 기전을 평가할 수 있게 됩니다. 3D 바이오프린팅과 같은 혁신 기술로 폐 구조를 더욱 정밀하게 모델링할 수 있게 되어 맞춤형 의료의 추진이 가속화됨에 따라 시장은 급속히 진화하고 있습니다. 또한 인공지능(AI)은 공정 자동화, 실험 조건 최적화, 생물학적 반응 예측을 통해 모델 개발을 강화하고 있으며, 이로 인해 막대한 투자를 유치하고 있습니다. 생명공학 기업과 AI 전문가 간의 협력은 ‘폐 온 칩(Lung-on-a-chip)’ 기술에 디지털 솔루션을 통합하려는 움직임을 부각시키고 있으며, 이는 시장 확대와 혁신의 가능성을 더욱 강화하고 있습니다.
세계의 체외 폐 모델 시장의 성장 요인
세계의 체외 폐 모델 시장은 인간 폐의 생리 기능을 보다 충실하게 재현하는 대안으로의 대대적인 전환에 힘입어 성장하고 있으며, 이로 인해 동물 실험에 대한 의존도가 낮아지고 있습니다. 이러한 전환은 윤리적 우려, 규제 당국의 지원, 그리고 의약품 개발에서 더 신뢰할 수 있는 예측 효과에 대한 수요에 힘입어 가속화되고 있습니다. 체외 폐 모델은 과학자들이 통제된 환경에서 조직의 반응을 관찰할 수 있는 실제와 유사한 세포 환경을 조성합니다. 그 결과, 제약 회사와 생명공학 기업은 신약 스크리닝의 초기 단계에서 이러한 모델을 점차 도입하고 있습니다. 이를 통해 후보 화합물 선정 과정이 효율화되고, 개발 후기 단계에서 막대한 손실을 수반하는 실패 위험이 감소함에 따라 전 세계적인 시장 발전이 촉진되고 있습니다.
전 세계 체외 폐 모델 시장의 제약 요인
생리학적으로 타당한 폐 모델의 개발에는 특수한 바이오소재, 신중한 세포 조달, 그리고 첨단 조립 기법에 의존하는 복잡한 과정이 수반되며, 이 모든 요소가 제조의 복잡성을 높이는 요인이 되고 있습니다. 서로 다른 로트 간에 일관된 품질을 확보하려면 철저한 검증과 첨단 기술을 갖춘 인력 채용이 필요하며, 이로 인해 운영 비용이 상승하고 있습니다. 이러한 재정적 및 절차적 과제는 중소규모 연구소가 이러한 첨단 기술을 도입하는 데 장애물이 되어, 결과적으로 시장 전체로의 확산을 제한하고 있습니다. 그 결과, 기존 방법에 비해 이러한 최신 분석법에 수반되는 비용이 높기 때문에 더 광범위한 활용이 저해되고, 시장 확대가 둔화될 가능성이 있습니다.
전 세계 체외 폐 모델 시장 동향
전 세계 체외 폐 모델 시장에서는 기증자 유래 1세대 세포나 맞춤형 세포외 기질을 활용한 환자 특이적 모델에 대한 수요가 증가함에 따라 개인 맞춤형 독성학 플랫폼으로의 큰 전환이 나타나고 있습니다. 이러한 동향에 따라 제약 개발자들은 기존의 범용 세포주에서 벗어나 개별 약물에 대한 반응 및 독성 프로파일을 보다 정확하게 예측할 수 있게 됩니다. 정밀 의학에 대한 노력은 개발 주기 단축 및 바이오뱅크와의 연계 강화로 이어질 뿐만 아니라, 세포 재프로그래밍 기술의 진보를 활용하여 다양한 표현형 라이브러리를 구축하는 데에도 기여하고 있습니다. 이러한 혁신을 통해 다양한 환자 집단에 대한 전임상 데이터의 관련성이 높아지고, 규제 당국의 승인 절차가 가속화되며, 전 세계 의약품 개발 프로세스가 변혁을 맞이하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 in vitro 폐 모델 시장 규모 : 유형별
세계의 in vitro 폐 모델 시장 규모 : 용도별
세계의 in vitro 폐 모델 시장 규모 : 세포원별
세계의 in vitro 폐 모델 시장 규모 : 최종사용자별
세계의 in vitro 폐 모델 시장 규모 : 질환 적응증별
세계의 in vitro 폐 모델 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.08.05Global In Vitro Lung Model Market size was valued at USD 341.6 Million in 2024 and is poised to grow from USD 391.54 Million in 2025 to USD 24.61 Million by 2033, growing at a CAGR of 14.62% during the forecast period (2026-2033).
The global in-vitro lung model market is significantly driven by the rising demand for alternatives to animal testing, influenced by strict regulatory standards and growing ethical considerations. Advanced in-vitro lung platforms, which range from basic epithelial cultures to intricate microfluidic systems, allow scientists to assess toxicity, efficacy, and disease mechanisms reflecting human physiology. The market is rapidly evolving due to innovations like 3D bioprinting, enabling more precise modeling of lung architecture and facilitating personalized medicine. Additionally, artificial intelligence is enhancing model development by automating processes, refining experimental conditions, and predicting biological responses, thereby attracting substantial investment. Collaborations between biotech companies and AI experts underscore a shift towards integrating digital solutions in lung-on-chip technologies, reinforcing the market's expansion and innovation potential.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global In Vitro Lung Model market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global In Vitro Lung Model Market Segments Analysis
Global in vitro lung model market is segmented by type, application, cell source, end user, disease indication and region. Based on type, the market is segmented into 2D Lung Cell Culture Models, 3D Lung Models, Lung-on-a-Chip Models, Precision-Cut Lung Slices (PCLS) and Organoid-Based Lung Models. Based on application, the market is segmented into Drug Discovery & Development, Toxicology Testing, Disease Modeling, Personalized Medicine, Regenerative Medicine Research and Other Research Applications. Based on cell source, the market is segmented into Primary Cells, Immortalized Cell Lines and Stem Cell-Derived Cells (Including iPSC-Derived). Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes and Regulatory & Government Research Laboratories. Based on disease indication, the market is segmented into Respiratory Infectious Diseases, Chronic Obstructive Pulmonary Disease (COPD), Asthma, Lung Cancer, Pulmonary Fibrosis and Other Respiratory Diseases. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global In Vitro Lung Model Market
The Global In Vitro Lung Model market is experiencing growth due to a significant transition towards alternatives that better mimic human lung physiology, which diminishes the dependency on animal testing. This transition is influenced by ethical concerns, regulatory support, and the demand for more reliable predictive effectiveness in drug development. In vitro lung models create authentic cellular environments that allow scientists to monitor tissue responses in a controlled setting. Consequently, pharmaceutical and biotechnology companies are progressively adopting these models during the early stages of drug screening, which streamlines candidate selection processes and reduces the risk of expensive failures during later development stages, driving market advancement on a global scale.
Restraints in the Global In Vitro Lung Model Market
The development of physiologically relevant lung models involves intricate processes that rely on specialized biomaterials, careful cell sourcing, and sophisticated assembly methods, all of which contribute to increased manufacturing complexity. Ensuring consistent quality across different batches necessitates thorough validation and the employment of highly skilled personnel, which drives up operational costs. These financial and procedural challenges create barriers for small and medium-sized laboratories in adopting such advanced technologies, thereby restricting overall market penetration. Consequently, the elevated costs associated with these modern assays, in comparison to conventional methods, may hinder broader usage and slow market expansion.
Market Trends of the Global In Vitro Lung Model Market
The Global In Vitro Lung Model market is witnessing a significant shift towards personalized toxicology platforms, driven by the growing demand for patient-specific models that utilize donor-derived primary cells and customized extracellular matrices. This trend enables pharmaceutical developers to make more accurate predictions regarding individual drug responses and toxicity profiles, moving away from traditional generic cell lines. The push for precision medicine is leading to shorter development cycles and greater collaboration with biobanks, as well as the leveraging of advances in cell reprogramming to create diverse phenotypic libraries. These innovations enhance the relevance of preclinical data for varied patient populations, facilitating faster regulatory acceptance and transforming drug development processes globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global In Vitro Lung Model Market Size by Type & CAGR (2026-2033)
- Market Overview
- 2D Lung Cell Culture Models
- 3D Lung Models
- Lung-on-a-Chip Models
- Precision-Cut Lung Slices (PCLS)
- Organoid-Based Lung Models
Global In Vitro Lung Model Market Size by Application & CAGR (2026-2033)
- Market Overview
- Drug Discovery & Development
- Toxicology Testing
- Disease Modeling
- Personalized Medicine
- Regenerative Medicine Research
- Other Research Applications
Global In Vitro Lung Model Market Size by Cell Source & CAGR (2026-2033)
- Market Overview
- Primary Cells
- Immortalized Cell Lines
- Stem Cell-Derived Cells (Including iPSC-Derived)
Global In Vitro Lung Model Market Size by End User & CAGR (2026-2033)
- Market Overview
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Regulatory & Government Research Laboratories
Global In Vitro Lung Model Market Size by Disease Indication & CAGR (2026-2033)
- Market Overview
- Respiratory Infectious Diseases
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Lung Cancer
- Pulmonary Fibrosis
- Other Respiratory Diseases
Global In Vitro Lung Model Market Size & CAGR (2026-2033)
- North America (Type, Application, Cell Source, End User, Disease Indication)
- US
- Canada
- Europe (Type, Application, Cell Source, End User, Disease Indication)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Application, Cell Source, End User, Disease Indication)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Application, Cell Source, End User, Disease Indication)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Application, Cell Source, End User, Disease Indication)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Emulate Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Mimetas B.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CN Bio Innovations Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AlveoliX AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- InSphero AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sartorius AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lonza Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PromoCell GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- MatTek Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Epithelix Sarl
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PhysioMimix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stemcell Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Organovo Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AxoSim Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- TissUse GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BiomimX S.r.l.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dynamic 42 GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kirkstall Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Newcells Biotech Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hesperos Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
